drugset / Trial / NCT03639922

Imatinib in Acute Ischaemic Stroke

NCT03639922

Phase 3 Unknown 1260 enrolled Niaz Ahmed
RandomizedParallel-groupTriple-blindTreatment

Summary

A clinical trial comparing treatment with Imatinib to placebo when administered within 8 hours of stroke onset for 6 days, in addition to conventional stroke treatment after acute ischaemic stroke.

Timeline

Start
2018-10-01
Primary completion
2022-12
Completion
2023-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Imatinib Small molecule 400 mg

Indications